Victor Kande Betu Kumeso likita ne ɗan ƙasar Kongo wanda kwararre ne a kan trypanosomiasis na Afirka. Yana aiki a Shirin National de Lutte contre la Trypanosomiase Humaine Africaine a Jami'ar Kinshasa.
Rayuwar farko da ilimi
Kande ya yi karatun likitanci. Yana da shekaru 27, shi kaɗai ne likita ga mutane 11,000 a lardin Bandundu.[1]
Bincike
An san Kande a matsayin uban ciwon barci (Father of sleeping sickness). An naɗa shi Daraktan shirin cutar bacci na Jamhuriyar Demokradiyyar Kongo kuma yana aiki tare da Ma'aikatar Lafiya ta Jama'a.[1][2] trypanosomiasis na Afirka yana shafar mutane da yawa a Jamhuriyar Demokradiyyar Kongo.[3] Trypanosoma brucei ne ke haifar da cutar kuma yawanci yana nunawa a cikin nau'i na yau da kullun.[4] Yana binciken cututtukan cututtukan barci.[5] Ya kasance daya daga cikin na farko da ya ba da rahoton sake bullar cutar barci, inda ya yi kira da a kara ba da taimako, haɗin gwiwa tsakanin ƙasashe da ingantattun wuraren kiwon lafiya da zaɓin magani.[6]
Kande ya kasance babban mai bincike na bincike da yawa na sabbin jiyya na trypanosomiasis na Afirka.[7] Ya binciki inganci da amincin DB289, wanda ake gudanarwa a matsayin ƙwaƙƙwaran magani ga Pentamidine. Ya kuma nuna babban rashin nasara tare da Melarsoprol kuma ya bincika amfani da Pafuramidine.[8] A cikin ƙasar da ke da ƙananan hanyoyi ko asibitoci, Kande da abokan aikinsa sun ɗauki mutane 400 da ke da matuƙar mataki na Trypanosoma brucei don gwajin Fexinidazole wanda shirin Drugs for Neglected Diseases initiative.[9][10] The study demonstrated that fexinidazole is an effective treatment for sleeping sickness.[11][12] Binciken ya nuna cewa fexinidazole magani ne mai mahimmanci ga ciwon barci.[10][11][12] An buga aikin a cikin The Lancet kuma ya jagoranci Kande da Richard Lehman (likitan kulawa na farko) ya bayyana shi 'jarumin likita na gaskiya'. Fexinidazole ya sami kyakkyawan ra'ayi daga Hukumar Kula da Magunguna ta Turai a ƙarƙashin Mataki na 58 a cikin watan Nuwamba 2018[13] kuma an yi rajista a cikin Jamhuriyar Demokradiyyar Kongo a cikin watan Disamba 2018.[14]
Kande a halin yanzu tana binciken SCYX-7158 (acoziborole) a matsayin magani guda ɗaya don ɗan adam na Trypanosomiasis (HAT) a cikin gwajin asibiti wanda shirin Drugs for Neglected Diseases initiative.[15][16]
Yana neman sabbin hanyoyin haɗin gwiwa tsakanin kamfanoni masu zaman kansu da na jama'a, kamar haɗin gwiwar da ya haifar da isar da fexinidazole ta DNDi.[17] A cikin shekarar 2018 Kande an ba shi lambar yabo ta Anne Maurer Cecchini na Taron Lafiya na Geneva.[12]
